Verastem Inc
$ 3.94
4.79%
11 Jun - close price
- Market Cap 335,677,000 USD
- Current Price $ 3.94
- High / Low $ 4.00 / 3.67
- Stock P/E N/A
- Book Value 0.74
- EPS -2.52
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.59 %
- ROE -7.86 %
- 52 Week High 11.25
- 52 Week Low 3.55
About
Verastem, Inc., a developing-stage biopharmaceutical company focused on developing and commercializing life-enhancing drugs for cancer patients. The company is headquartered in Needham, Massachusetts.
Analyst Target Price
$16.00
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-07 | 2026-03-04 | 2025-11-04 | 2025-08-07 | 2025-05-13 | 2025-03-20 | 2024-11-06 | 2024-08-08 | 2024-05-09 | 2024-03-14 | 2023-11-08 | 2023-08-08 |
| Reported EPS | -0.43 | -0.4592 | -1.35 | -0.62 | -0.79 | -0.6 | -0.6 | -0.31 | -1.26 | -1.02 | -0.75 | -1.37 |
| Estimated EPS | -0.4667 | -0.4967 | -0.87 | -0.88 | -0.775 | -0.7367 | -0.74 | -0.95 | -1 | -0.62 | -0.84 | -1.06 |
| Surprise | 0.0367 | 0.0375 | -0.48 | 0.26 | -0.015 | 0.1367 | 0.14 | 0.64 | -0.26 | -0.4 | 0.09 | -0.31 |
| Surprise Percentage | 7.8637% | 7.5498% | -55.1724% | 29.5455% | -1.9355% | 18.5557% | 18.9189% | 67.3684% | -26% | -64.5161% | 10.7143% | -29.2453% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: VSTM
2026-06-08 22:39:22
Verastem (Nasdaq:VSTM) is a development-stage biopharmaceutical company focused on cancer treatments, with its stock currently trading at US$3.76, significantly undervalued according to analysts. The company shows strong future revenue growth forecasts and positive analyst sentiment, despite being unprofitable and having seen substantial shareholder dilution and insider selling. Recent developments include FDA approval for AVMAPKI FAKZYNJA CO-PACK for KRAS-mutated LGSOC, positive clinical trial data for other pipeline candidates, and changes to its board and management.
2026-06-08 04:39:33
The article provides a technical analysis of Verastem Inc (VSTM), indicating a "Strong Sell" consensus based on various technical signals. It details momentum indicators, support and resistance levels, and moving averages, all of which generally suggest a bearish outlook for the stock. VSTM's share price is currently below its significant moving averages, reinforcing the negative technical sentiment.
2026-06-04 00:41:06
Verastem Oncology announced that its investigational drug VS-7375 has received FDA Fast Track Designation for treating adult patients with KRAS G12D-mutated non-small cell lung cancer previously treated with platinum-based chemotherapy and an anti-PD-(L)1 antibody. This marks the second Fast Track designation for VS-7375, which was previously recognized for pancreatic cancer. The company is currently conducting multiple Phase 2 clinical trials for the drug in various KRAS G12D-mutated solid tumors, including lung, pancreatic, and colorectal cancers.
2026-06-03 21:41:06
Verastem Oncology's stock gained 4% in after-hours trading after the FDA granted Fast Track Designation to its drug VS-7375 for KRAS G12D-mutated non-small cell lung cancer. This designation applies to adult patients who have undergone prior chemotherapy and anti-PD-(L)1 therapy. The same drug previously received Fast Track Designation for KRAS G12D-mutated pancreatic cancer in July 2025.
2026-06-03 20:09:27
Verastem Inc. (VSTM) has received Fast Track Designation from the FDA for its investigational drug VS-7375, a KRAS G12D inhibitor, for treating advanced NSCLC after prior therapies. This designation accelerates development for a significant subset of lung cancer patients with unmet needs. Despite this positive development, Verastem holds a low GF Score™ of 19/100, indicating financial challenges and profitability issues, while valuation metrics suggest potential overvaluation.
2026-06-03 19:41:06
Verastem (VSTM) has initiated a Phase 2 trial, named Target-D 202, for advanced Non-Small Cell Lung Cancer (NSCLC). The information is provided by Refinitiv and states that the article is less than a minute read.
